Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.
De Vecchis R, Esposito C, Ariano C.
Herz · meta-analysis; systematic review; journal article · DOI 10.1007/s00059-013-3816-0 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för cabergoline. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
5 hitsShort-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas.
Garcia EC, Naves LA, Silva AO, de Castro LF, Casulari LA, Azevedo MF.
Pituitary · journal article · DOI 10.1007/s11102-012-0403-yCabergoline as treatment of ovarian hyperstimulation syndrome: a review.
Kalampokas T, Creatsas G, Kalampokas E.
Gynecol Endocrinol · review; journal article · DOI 10.3109/09513590.2012.730578Cabergoline for preventing ovarian hyperstimulation syndrome.
Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ.
Cochrane Database Syst Rev · meta-analysis; systematic review; journal article · DOI 10.1002/14651858.cd008605.pub2Acute shrinkage of a giant prolactinoma, masquerading as an erosive skull base tumour, with cabergoline.
Dash S, Annamalai AK, Simpson HL, Sarkies N, Antoun NM, Mannion R.
QJM · journal article; case reports · DOI 10.1093/qjmed/hcr221